|
WO2019136305A1
|
|
Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer
|
|
WO2019126384A1
|
|
Effective il-12 dosing regimens
|
|
CA3031083A1
|
|
Uses of il-12 as a replacement immunotherapeutic
|
|
CA2966217A1
|
|
Il-12 compositions and methods of use in hematopoietic recovery
|
|
KR20170088861A
|
|
Uses of il-12 as an hematopoietic immunotherapy(hit)
|
|
US2015343021A1
|
|
Methods for treating cancer using compositions comprising hss1 and/or hsm1
|
|
US2015147294A1
|
|
Use of il-12 to increase survival
|
|
WO2014160318A1
|
|
Endogenous vaccine for cancer and infectious diseases
|
|
US2013243722A1
|
|
Methods for radiation protection by administering IL-12
|
|
WO2013016634A1
|
|
Use of il-12 to generate endogenous erythropoietin
|
|
EP2718456A1
|
|
Mitigation of cutaneous injury with il-12
|
|
CA2812310A1
|
|
Uses of il-12 and the il-12 receptor positive cell in tissue repair and regeneration
|
|
WO2011146574A1
|
|
Il-12 formulations for enhancing hematopoiesis
|
|
WO2011094446A1
|
|
A method for treating brain cancer using a novel tumor suppressor gene and secreted factor
|
